) is an anti-convulsive medication
produced by Cephalon
and marketed under the brand name Gabitril
. The drug was discovered at Novo Nordisk in Denmark in 1988. and was co-developed with Abbott. After a period of co-promotion, Cephalon licensed Tiagabine from Abbott/Novo and now are the exclusive producer. The medication is also used in the treatment of panic disorder
as are a few other anticonvulsants.
Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, evidence is available that it operates as a selective GABA reuptake inhibitor.
Tiagabine's most common side effects include confusion, difficulty speaking clearly/stuttering, mild sedation, and in doses over 8 mg, a tingling sensation (paresthesia) in the body's extremities, particularly the hands and fingers.